MIAMI and VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to ...

Dr. Mackey’s project, “ Regenerating healthy human skeletal muscle at single nucleus resolution ,” will create the most detailed molecular map to date of how healthy human muscle repairs itself. The ...

DelveInsight's“ Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in the Facioscapulohumeral Muscular ...

Please provide your email address to receive an email when new articles are posted on . Treatment with losmapimod and placebo had similar results with respect to primary, secondary endpoints. No ...

Please provide your email address to receive an email when new articles are posted on . Safety and tolerability of losmapimod were assessed in 108 people with facioscapulohumeral muscular dystrophy.

VANCOUVER, British Columbia--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to catalyzing innovation and overcoming barriers to accelerate new therapies for ...

There are numerous forms of Muscular Dystrophy. For those of us who are affected by it (and for people who don’t know much about the disease) this can be very confusing! I suffer from a particular ...

An experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy ...

Facioscapulohumeral muscular dystrophy (FSHD) is the most common of the nine primary types of muscular dystrophy. Studies once estimated prevalence to be about 1 in 20,000 people, according to the FSH ...

DelveInsight’s “Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in the Facioscapulohumeral Muscular ...